Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial

Progression-free survival and overall survival of patients with early recurrence within 6 months after the completion of S-1 adjuvant therapy and those with late recurrence more than 6 months or later after the completion of S-1 adjuvant therapy. (A) Kaplan–Meier curves for progression-free survival among patients with early recurrence within 6 months after the completion of S-1 adjuvant therapy and those with late recurrence more than 6 months or later after the completion of S-1 adjuvant therapy. (B) Kaplan–Meier curves for overall survival among patients with early recurrence within 6 months after completion of S-1 adjuvant therapy and those with late recurrence more than 6 months after the completion of S-1 adjuvant therapy.